Pharmaceutical

Agilent agrees to acquire BIOVECTRA for $925m

Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.

Jul 24, 2024 - 04:00
Agilent agrees to acquire BIOVECTRA for $925m
Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.
Read the original article

Tags:

Previous Article

Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Se...

Next Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharma’s attack on Medicare drug price negotiation might benefit Biden

STAT+: Pharma’s attack on Medicare drug price negotiati...

Jan 24, 2024

Novaliq pursues EMA approval for dry eye disease drug

Novaliq pursues EMA approval for dry eye disease drug

Aug 24, 2023

Opinion: STAT readers on diagnostic tests, marijuana regulation, and pediatric oncology

Opinion: STAT readers on diagnostic tests, marijuana re...

Dec 9, 2023